Abstract
Despite the increasing use and success of interventional coronary reperfusion strategies, morbidity and mortality from acute myocardial infarction are still substantial. Myocardial infarct size is a major determinant of prognosis in these patients. Therefore, cardioprotective strategies aim to reduce infarct size. However, a perplexing gap exists between the many preclinical studies reporting infarct size reduction with mechanical and pharmacological interventions and the poor translation into better clinical outcomes in patients. This Review revisits the pathophysiology of myocardial ischaemia–reperfusion injury, including the role of autophagy and forms of cell death such as necrosis, apoptosis, necroptosis and pyroptosis. Other cellular compartments in addition to cardiomyocytes are addressed, notably the coronary microcirculation. Preclinical and clinical research developments in mechanical and pharmacological approaches to induce cardioprotection, and their signal transduction pathways, are discussed. Additive cardioprotective interventions are advocated. For clinical translation into treatments for patients with acute myocardial infarction, who typically are of advanced age, have comorbidities and are receiving several medications, not only infarct size reduction but also attenuation of coronary microvascular obstruction, as well as longer-term targets including infarct repair and reverse remodelling, must be considered to improve patient outcomes. Future clinical trials must focus on patients who really need adjunct cardioprotection, that is, those with severe haemodynamic alterations.
Key points
-
Sustained myocardial ischaemia–reperfusion induces various modes of cardiomyocyte death and coronary microvascular injury.
-
Ischaemic conditioning (cycles of brief ischaemia–reperfusion in the heart or in a tissue remote from the heart) reduces infarct size and coronary microvascular injury.
-
The signalling pathways triggered by ischaemic conditioning are complex and include activation of sarcolemmal receptors and cytosolic kinases, as well as reduced mitochondrial permeability transition pore opening, Ca2+ overload and proteolysis.
-
Ischaemic postconditioning and remote ischaemic conditioning reduced infarct size in patients with ST-segment elevation myocardial infarction in proof-of-concept trials.
-
Remote ischaemic conditioning improved clinical outcomes in patients with ST-segment elevation myocardial infarction in one phase III clinical trial.
-
In future studies, the use of additive cardioprotective strategies and a focus on patients with severe haemodynamic alterations (such as cardiogenic shock or those in Killip class III–IV) are advocated.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Heusch, G. Cardioprotection: chances and challenges of its translation to the clinic. Lancet 381, 166–175 (2013).
Heusch, G. Myocardial ischemia: lack of coronary blood flow, myocardial oxygen supply-demand imbalance, or what? Am. J. Physiol. Heart Circ. Physiol. 316, H1439–H1446 (2019).
Ibanez, B. et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 39, 119–177 (2017).
Ginks, W. R. et al. Coronary artery reperfusion. II. Reduction of myocardial infarct size at 1 week after the coronary occlusion. J. Clin. Invest. 51, 2717–2723 (1972).
Ibanez, B., Heusch, G., Ovize, M. & Van de Werf, F. Evolving therapies for myocardial ischemia/reperfusion injury. J. Am. Coll. Cardiol. 65, 1454–1471 (2015).
Piper, H. M., García-Dorado, D. & Ovize, M. A fresh look at reperfusion injury. Cardiovasc. Res. 38, 291–300 (1998).
Heusch, G. Treatment of myocardial ischemia/reperfusion injury by ischemic and pharmacological postconditioning. Compr. Physiol. 5, 1123–1145 (2015).
Hausenloy, D. J. et al. Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction: trials and tribulations. Eur. Heart J. 38, 935–941 (2017).
Hausenloy, D. J. & Yellon, D. M. Myocardial ischemia–reperfusion injury: a neglected therapeutic target. J. Clin. Invest. 123, 92–100 (2013).
Moran, A. E. et al. The global burden of ischemic heart disease in 1990 and 2010: the Global Burden of Disease 2010 study. Circulation 129, 1493–1501 (2014).
Roe, M. T. et al. Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention. J. Am. Coll. Cardiol. 56, 254–263 (2010).
Cung, T. T. et al. Cyclosporine before PCI in patients with acute myocardial infarction. N. Engl. J. Med. 373, 1021–1103 (2015).
Hausenloy, D. J. et al. Effect of remote ischemic conditioning on clinical outcomes at 12 months in acute myocardial infarction patients: the CONDI-2/ERIC-PPCI trial. Lancet 394, 1415–1424 (2019).
Jernberg, T. et al. Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction. JAMA 305, 1677–1684 (2011).
Heusch, G. & Gersh, B. J. The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: a continual challenge. Eur. Heart J. 38, 774–784 (2017).
Stone, G. W. et al. Relationship between infarct size and outcomes following primary PCI: patient-level analysis from 10 randomized trials. J. Am. Coll. Cardiol. 67, 1674–1683 (2016).
Murry, C. E., Jennings, R. B. & Reimer, K. A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74, 1124–1136 (1986).
Hausenloy, D. J. et al. Ischaemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery. Basic Res. Cardiol. 111, 70 (2016).
Heusch, G. & Rassaf, T. Time to give up on cardioprotection? A critical appraisal of clinical studies on ischemic pre-, post-, and remote conditioning. Circ. Res. 119, 676–695 (2016).
Heusch, G. Critical issues for the translation of cardioprotection. Circ. Res. 120, 1477–1486 (2017).
Gaspar, A. et al. Randomized controlled trial of remote ischaemic conditioning in ST-elevation myocardial infarction as adjuvant to primary angioplasty (RIC-STEMI). Basic Res. Cardiol. 113, 14 (2018).
Heusch, G. 25 years of remote ischemic conditioning: from laboratory curiosity to clinical outcome. Basic Res. Cardiol. 113, 15 (2018).
Kloner, R. A. et al. New and revisited approaches to preserving the reperfused myocardium. Nat. Rev. Cardiol. 14, 679–693 (2017).
Jennings, R. B. & Reimer, K. A. Lethal myocardial ischemic injury. Am. J. Pathol. 102, 241–255 (1981).
Przyklenk, K. Lethal myocardial “reperfusion injury”: the opinions of good men. J. Thromb. Thrombolysis 4, 5–6 (1997).
Zhao, Z.-Q. et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am. J. Physiol. Heart Circ. Physiol 285, H579–H588 (2003).
Tissier, R., Ghaleh, B., Cohen, M. V., Downey, J. M. & Berdeaux, A. Myocardial protection with mild hypothermia. Cardiovasc. Res. 94, 217–225 (2012).
Heusch, G. Vagal cardioprotection in reperfused acute myocardial infarction. JACC Cardiovasc. Interv. 10, 1521–1522 (2017).
Kleinbongard, P., Amanakis, G., Skyschally, A. & Heusch, G. Reflection of cardioprotection by remote ischemic perconditioning in attenuated ST-segment elevation during ongoing coronary occlusion in pigs: evidence for cardioprotection from ischemic injury. Circ. Res. 122, 1102–1108 (2018).
Garcia-Ruiz, J. M. et al. Impact of the timing of metoprolol administration during STEMI on infarct size and ventricular function. J. Am. Coll. Cardiol. 67, 2093–2104 (2016).
Bøtker, H. E. et al. Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection. Basic Res. Cardiol. 113, 39 (2018).
Reimer, K. A., Lowe, J. E., Rasmussen, M. M. & Jennings, R. B. The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation 56, 786–794 (1977).
Reimer, K. A. & Jennings, R. B. The “wavefront phenomenon” of myocardial ischemic cell death. II. Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. Lab. Invest. 40, 633–644 (1979).
Mishra, P. K. et al. Guidelines for evaluating myocardial cell death. Am. J. Physiol. Heart Circ. Physiol. 317, H891–H922 (2019).
Tani, M. & Neely, J. R. Role of intracellular Na+ in Ca2+ overload and depressed recovery of ventricular function of reperfused ischemic rat hearts. Circ. Res. 65, 1045–1056 (1989).
Ladilov, Y. V., Siegmund, B. & Piper, H. M. Protection of reoxygenated cardiomyocytes against hypercontracture by inhibition of Na+/H+ exchange. Am. J. Physiol. 268, H1531–H1539 (1995).
Piper, H. M., Meuter, K. & Schäfer, C. Cellular mechanisms of ischemia–reperfusion injury. Ann. Thorac. Surg. 75, S644–S648 (2003).
Schlüter, K. D., Jakob, G., Ruiz-Meana, G. J. M., Garcia-Dorado, D. & Piper, H. M. Protection of reoxygenated cardiomyocytes against osmotic fragility by nitric oxide donors. Am. J. Physiol. Heart Circ. Physiol. 271, H428–H434 (1996).
Inserte, J., Hernando, V. & Garcia-Dorado, D. Contribution of calpains to myocardial ischaemia/reperfusion injury. Cardiovasc. Res. 96, 23–31 (2012).
Davidson, S. M. et al. Mitochondrial and mitochondrial-independent pathways of myocardial cell death during ischaemia and reperfusion injury. J. Cell Mol. Med. 24, 3795–3806 (2020).
Hengartner, M. O. The biochemistry of apoptosis. Nature 407, 770–776 (2000).
Bernardi, P., Rasola, A., Forte, M. & Lippe, G. The mitochondrial permeability transition pore: channel formation by F-ATP synthase, integration in signal transduction, and role in pathophysiology. Physiol. Rev. 95, 1111–1155 (2015).
Bernardi, P. & Di Lisa, F. The mitochondrial permeability transition pore: molecular nature and role as a target in cardioprotection. J. Mol. Cell Cardiol. 78c, 100–106 (2015).
Zhou, W. & Yuan, J. SnapShot: necroptosis. Cell 158, 464–464.e1 (2014).
Oerlemans, M. I. et al. Inhibition of RIP1-dependent necrosis prevents adverse cardiac remodeling after myocardial ischemia–reperfusion in vivo. Basic Res. Cardiol. 107, 270 (2012).
Kawaguchi, M. et al. Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation 123, 594–604 (2011).
Audia, J. P. et al. Caspase-1 inhibition by VX-765 administered at reperfusion in P2Y12 receptor antagonist-treated rats provides long-term reduction in myocardial infarct size and preservation of ventricular function. Basic Res. Cardiol. 113, 32 (2018).
Gottlieb, R. A. & Mentzer, R. M. Jr. Autophagy: an affair of the heart. Heart Fail. Rev. 18, 575–584 (2013).
Dong, Y., Undyala, V. V., Gottlieb, R. A., Mentzer, R. M. Jr & Przyklenk, K. Autophagy: definition, molecular machinery, and potential role in myocardial ischemia–reperfusion injury. J. Cardiovasc. Pharmacol. Ther. 15, 220–230 (2010).
Sala-Mercado, J. A. et al. Profound cardioprotection with chloramphenicol succinate in the swine model of myocardial ischemia–reperfusion injury. Circulation 122, S179–S184 (2010).
Heusch, G., Schulz, R., Baumgart, D., Haude, M. & Erbel, R. Coronary microembolization. Prog. Cardiovasc. Dis. 44, 217–230 (2001).
Koshinuma, S., Miyamae, M., Kaneda, K., Kotani, J. & Figueredo, V. M. Combination of necroptosis and apoptosis inhibition enhances cardioprotection against myocardial ischemia–reperfusion injury. J. Anesth. 28, 235–241 (2014).
Heusch, G. et al. The coronary circulation in cardioprotection: more than just one confounder. Cardiovasc. Res. 94, 237–245 (2012).
Heusch, G. The coronary circulation as a target of cardioprotection. Circ. Res. 118, 1643–1658 (2016).
Heusch, G. Coronary microvascular obstruction: the new frontier in cardioprotection. Basic Res. Cardiol. 114, 45 (2019).
Niccoli, G. et al. Optimized treatment of ST-elevation myocardial infarction: the unmet need to target coronary microvascular obstruction as primary treatment goal to further improve prognosis. Circ. Res. 125, 245–258 (2019).
Heusch, G. et al. Coronary microembolization: from bedside to bench and back to bedside. Circulation 120, 1822–1836 (2009).
Kleinbongard, P. et al. Vasoconstrictor potential of coronary aspirate from patients undergoing stenting of saphenous vein aortocoronary bypass grafts and its pharmacological attenuation. Circ. Res. 108, 344–352 (2011).
Kleinbongard, P. et al. Aspirate from human stented native coronary arteries vs. saphenous vein grafts: more endothelin but less particulate debris. Am. J. Physiol. Heart Circ. Physiol. 305, H1222–H1229 (2013).
Bolli, R., Triana, J. F. & Jeroudi, M. O. Prolonged impairment of coronary vasodilation after reversible ischemia. Circ. Res. 67, 332–343 (1990).
Ehring, T. et al. Cholinergic and α-adrenergic coronary vasomotion with increasing ischemia–reperfusion injury. Am. J. Physiol. 268, H886–H894 (1995).
Sheridan, F. M., Dauber, I. M., McMurtry, I. F., Lesnefsky, E. J. & Horwitz, L. D. Role of leukocytes in coronary vascular endothelial injury due to ischemia and reperfusion. Circ. Res. 69, 1566–1574 (1991).
Barrabes, J. A. et al. Antagonism of selectin function attenuates microvascular platelet deposition and platelet-mediated myocardial injury after transient ischemia. J. Am. Coll. Cardiol. 45, 293–299 (2005).
Driesen, R. B. et al. Histological correlate of a cardiac magnetic resonance imaged microvascular obstruction in a porcine model of ischemia–reperfusion. Cardiovasc. Pathol. 21, 129–131 (2011).
Dauber, I. M. et al. Functional coronary microvascular injury evident as increased permeability due to brief ischemia and reperfusion. Circ. Res. 66, 986–998 (1990).
Garcia-Dorado, D., Andres-Villarreal, M., Ruiz-Meana, M., Inserte, J. & Barba, I. Myocardial edema: a translational view. J. Mol. Cell Cardiol. 52, 931–939 (2012).
Krug, A., du Mesnil de Rochemont, W. & Korb, G. Blood supply of the myocardium after temporary coronary occlusion. Circ. Res. 19, 57–62 (1966).
Kloner, R. A., Ganote, C. E. & Jennings, R. B. The “no-reflow” phenomenon after temporary coronary occlusion in the dog. J. Clin. Invest. 54, 1496–1508 (1974).
Higginson, L. A. et al. Determinants of myocardial hemorrhage after coronary reperfusion in the anesthetized dog. Circulation 65, 62–69 (1982).
Robbers, L. F. et al. Magnetic resonance imaging-defined areas of microvascular obstruction after acute myocardial infarction represent microvascular destruction and haemorrhage. Eur. Heart J. 34, 2346–2353 (2013).
Hori, M. et al. Role of oxygen-derived free radicals in myocardial edema and ischemia in coronary microvascular embolization. Circulation 84, 828–840 (1991).
de Waha, S. et al. Relationship between microvascular obstruction and adverse events following primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an individual patient data pooled analysis from seven randomized trials. Eur. Heart J. 38, 3502–3510 (2017).
Murry, C. E., Richard, V. J., Jennings, R. B. & Reimer, K. A. Myocardial protection is lost before contractile function recovers from ischemic preconditioning. Am. J. Physiol. Heart Circ. Physiol. 260, H796–H804 (1991).
Marber, M. S., Latchman, D. S., Walker, J. M. & Yellon, D. M. Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction. Circulation 88, 1264–1272 (1993).
Bolli, R. The late phase of preconditioning. Circ. Res. 87, 972–983 (2000).
Heusch, G. Nitroglycerin and delayed preconditioning in humans. Yet another new mechanism for an old drug? Circulation 103, 2876–2878 (2001).
Rezkalla, S. H. & Kloner, R. A. Ischemic preconditioning and preinfarction angina in the clinical arena. Nat. Clin. Pract. Cardiovasc. Med. 1, 96–102 (2004).
Deutsch, E. et al. Adaptation to ischemia during percutaneous transluminal coronary angioplasty. Clinical, hemodynamic, and metabolic features. Circulation 82, 2044–2051 (1990).
Tomai, F. et al. Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker. Circulation 90, 700–705 (1994).
Yellon, D. M., Alkhulaifi, A. M. & Pugsley, W. B. Preconditioning the human myocardium. Lancet 342, 276–277 (1993).
Jenkins, D. P. et al. Ischaemic preconditioning reduces troponin T release in patients undergoing coronary artery bypass surgery. Heart 77, 314–318 (1997).
Staat, P. et al. Postconditioning the human heart. Circulation 112, 2143–2148 (2005).
Thuny, F. et al. Post-conditioning reduces infarct size and edema in patients with ST-segment elevation myocardial infarction. J. Am. Coll. Cardiol. 59, 2175–2181 (2012).
Mewton, N. et al. Postconditioning attenuates no-reflow in STEMI patients. Basic Res. Cardiol. 108, 383 (2013).
Traverse, J. H. et al. NHLBI-sponsored randomized trial of postconditioning during primary percutaneous coronary intervention for ST-elevation myocardial infarction. Circ. Res. 124, 769–778 (2019).
Thibault, H. et al. Long-term benefit of postconditioning. Circulation 117, 1037–1044 (2008).
Ma, X. J., Zhang, X. H., Li, C. M. & Luo, M. Effect of postconditioning on coronary blood flow velocity and endothelial function in patients with acute myocardial infarction. Scand. Cardiovasc. J. 40, 327–333 (2006).
Yang, X. C. et al. Reduction in myocardial infarct size by postconditioning in patients after percutaneous coronary intervention. J. Invasive Cardiol. 19, 424–430 (2007).
Laskey, W. K., Yoon, S., Calzada, N. & Ricciardi, M. J. Concordant improvements in coronary flow reserve and ST-segment resolution during percutaneous coronary intervention for acute myocardial infarction: a benefit of postconditioning. Catheter. Cardiovasc. Interv. 72, 212–220 (2008).
Zhao, W. S. et al. A 60-s postconditioning protocol by percutaneous coronary intervention inhibits myocardial apoptosis in patients with acute myocardial infarction. Apoptosis 14, 1204–1211 (2009).
Lonborg, J. et al. Cardioprotective effects of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonance. Circ. Cardiovasc. Interv. 3, 34–41 (2010).
Sörensson, P. et al. Effect of postconditioning on infarct size in patients with ST elevation myocardial infarction. Heart 96, 1710–1715 (2010).
Xue, F. et al. Postconditioning the human heart in percutaneous coronary intervention. Clin. Cardiol. 33, 439–444 (2010).
Garcia, S. et al. Long-term follow-up of patients undergoing postconditioning during ST-elevation myocardial infarction. J. Cardiovasc. Transl. Res. 4, 92–98 (2011).
Liu, T. K., Mishra, A. K. & Ding, F. X. Protective effect of ischemia postconditioning on reperfusion injury in patients with ST-segment elevation acute myocardial infarction [Chinese]. Zhonghua Xin Xue Guan Bing Za Zhi 39, 35–39 (2011).
Freixa, X. et al. Ischaemic postconditioning revisited: lack of effects on infarct size following primary percutaneous coronary intervention. Eur. Heart J. 33, 103–112 (2012).
Tarantini, G. et al. Postconditioning during coronary angioplasty in acute myocardial infarction: the POST-AMI trial. Int. J. Cardiol. 162, 33–38 (2012).
Ugata, Y., Nakamura, T., Taniguchi, Y., Ako, J. & Momomura, S. Effect of postconditioning in patients with ST-elevation acute myocardial infarction. Cardiovasc. Interv. Ther. 27, 14–18 (2012).
Dwyer, N. B. et al. No cardioprotective benefit of ischemic postconditioning in patients with ST-segment elevation myocardial infarction. J. Interv. Cardiol. 26, 482–490 (2013).
Elzbieciak, M. et al. Effect of postconditioning on infarction size, adverse left ventricular remodeling, and improvement in left ventricular systolic function in patients with first anterior ST segment elevation myocardial infarction. Pol. Arch. Med. Wewn. 123, 268–276 (2013).
Hahn, J. Y. et al. Ischemic postconditioning during primary percutaneous coronary intervention: the POST randomized trial. Circulation 128, 1889–1896 (2013).
Liu, S. H., Huo, Y. E., Yin, B. Y., Li, X. H. & Wang, Y. F. Ischemic postconditioning may increase serum fetuin-A level in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous intervention. Clin. Lab. 59, 59–64 (2013).
Araszkiewicz, A. et al. Postconditioning reduces enzymatic infarct size and improves microvascular reperfusion in patients with ST-segment elevation myocardial infarction. Cardiology 129, 250–257 (2014).
Bodi, V. et al. Effect of ischemic postconditioning on microvascular obstruction in reperfused myocardial infarction. Results of a randomized study in patients and of an experimental model in swine. Int. J. Cardiol. 175, 138–146 (2014).
Dong, M. et al. The beneficial effects of postconditioning on no-reflow phenomenon after percutaneous coronary intervention in patients with ST-elevation acute myocardial infarction. J. Thromb. Thrombolysis 38, 208–214 (2014).
Limalanathan, S. et al. Effect of ischemic postconditioning on infarct size in patients with ST-elevation myocardial infarction treated by primary PCI: results of the POSTEMI (Postconditioning in ST-Elevation Myocardial Infarction) randomized trial. J. Am. Heart Assoc. 3, e000679 (2014).
Luz, A. et al. Lack of benefit of ischemic postconditioning after routine thrombus aspiration during reperfusion: immediate and midterm results. J. Cardiovasc. Pharmacol. Ther. 20, 523–531 (2015).
Yetgin, T. et al. Impact of multiple balloon inflations during primary percutaneous coronary intervention on infarct size and long-term clinical outcomes in ST-segment elevation myocardial infarction: real-world postconditioning. Basic Res. Cardiol. 109, 403 (2014).
Eitel, I. et al. Cardioprotection by combined intrahospital remote ischaemic perconditioning and postconditioning in ST-elevation myocardial infarction: the randomized LIPSIA CONDITIONING trial. Eur. Heart J. 36, 3049–3057 (2015).
Kim, E. K. et al. Effect of ischemic postconditioning on myocardial salvage in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: cardiac magnetic resonance substudy of the POST randomized trial. Int. J. Cardiovasc. Imaging 31, 629–637 (2015).
Engstrøm, T. et al. Effect of ischemic postconditioning during primary percutaneous coronary intervention for patients with ST-segment elevation myocardial infarction: a randomized clinical trial. JAMA Cardiol. 2, 490–497 (2017).
Araszkiewicz, A. et al. Ischemic postconditioning reduces infarct size and microvascular obstruction zone in acute ST-elevation myocardial infarction — a randomized study. Postepy Kardiol Interwencyjnej 15, 292–300 (2019).
Mukherjee, P. & Jain, M. Effect of ischemic postconditioning during primary percutaneous coronary intervention for patients with ST-segment elevation myocardial infarction: a single-center cross-sectional study. Ann. Card. Anaesth. 22, 347–352 (2019).
Przyklenk, K., Bauer, B., Ovize, M., Kloner, R. A. & Whittaker, P. Regional ischemic “preconditioning” protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation 87, 893–899 (1993).
Heusch, G., Bøtker, H. E., Przyklenk, K., Redington, A. & Yellon, D. Remote ischemic conditioning. J. Am. Coll. Cardiol. 65, 177–195 (2015).
Kleinbongard, P., Skyschally, A. & Heusch, G. Cardioprotection by remote ischemic conditioning and its signal transduction. Pflugers Arch. 469, 159–181 (2017).
Bøtker, H. E. et al. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet 375, 727–734 (2010).
Sloth, A. D. et al. Improved long-term clinical outcomes in patients with ST-elevation myocardial infarction undergoing remote ischaemic conditioning as an adjunct to primary percutaneous coronary intervention. Eur. Heart J. 35, 168–175 (2014).
Munk, K. et al. Remote ischemic conditioning in patients with myocardial infarction treated with primary angioplasty: impact on left ventricular function assessed by comprehensive echocardiography and gated single-photon emission CT. Circ. Cardiovasc. Imaging 3, 656–662 (2010).
Rentoukas, I. et al. Cardioprotective role of remote ischemic periconditioning in primary percutaneous coronary intervention: enhancement by opioid action. J. Am. Coll. Cardiol. Cardiovasc. Interv. 3, 49–55 (2010).
Crimi, G. et al. Remote ischemic post-conditioning of the lower limb during primary percutaneous coronary intervention safely reduces enzymatic infarct size in anterior myocardial infarction: a randomized controlled trial. J. Am. Coll. Cardiol. Cardiovasc. Interv. 6, 1055–1063 (2013).
Prunier, F. et al. The RIPOST-MI study, assessing remote ischemic perconditioning alone or in combination with local ischemic postconditioning in ST-segment elevation myocardial infarction. Basic Res. Cardiol. 109, 400 (2014).
White, S. K. et al. Remote ischemic conditioning reduces myocardial infarct size and edema in patients with ST-segment elevation myocardial infarction. J. Am. Coll. Cardiol. Cardiovasc. Interv. 8, 178–188 (2015).
Yamanaka, T. et al. Remote ischemic preconditioning reduces contrast-induced acute kidney injury in patients with ST-elevation myocardial infarction: a randomized controlled trial. Int. J. Cardiol. 178, 136–141 (2015).
Yellon, D. M. et al. Remote ischemic conditioning reduces myocardial infarct size in STEMI patients treated by thrombolysis. J. Am. Coll. Cardiol. 65, 2764–2765 (2015).
Liu, Z., Zhao, L., Hong, D. & Gao, J. Remote ischaemic preconditioning reduces myocardial ischaemic reperfusion injury in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Acta Cardiol. 71, 596–603 (2016).
Verouhis, D. et al. Effect of remote ischemic conditioning on infarct size in patients with anterior ST-elevation myocardial infarction. Am. Heart J. 181, 66–73 (2016).
Elbadawi, A. et al. Impact of remote ischemic postconditioning during primary percutaneous coronary intervention on left ventricular remodeling after anterior wall ST-segment elevation myocardial infarction: a single-center experience. Int. J. Angiol. 26, 241–248 (2017).
Ladejobi, A. et al. Association of remote ischemic peri-conditioning with reduced incidence of clinical heart failure after primary percutaneous coronary intervention. Cardiovasc. Revasc. Med. 18, 105–109 (2017).
Cao, B., Wang, H., Zhang, C., Xia, M. & Yang, X. Remote ischemic postconditioning (RIPC) of the upper arm results in protection from cardiac ischemia–reperfusion injury following primary percutaneous coronary intervention (PCI) for acute ST-segment elevation myocardial infarction (STEMI). Med. Sci. Monit. 24, 1017–1026 (2018).
Ghaffari, S., Pourafkari, L., Manzouri, S. & Nader, N. D. Effect of remote ischemic postconditioning during thrombolysis in STEMI. Herz 43, 161–168 (2018).
Cheskes, S. et al. Field implementation of remote ischemic conditioning in ST-elevation myocardial infarction: the FIRST study. Can. J. Cardiol. https://doi.org/10.1016/j.cjca.2019.11.029 (2020).
Thourani, V. H. et al. Ischemic preconditioning attenuates postischemic coronary artery endothelial dysfunction in a model of minimally invasive direct coronary artery bypass. J. Thorac. Cardiovasc. Surg. 117, 383–389 (1999).
Tofukuji, M. et al. Effects of ischemic preconditioning on myocardial perfusion, function, and microvascular regulation. Circulation 98, II-197–II-205 (1998).
Kurzelewski, M., Czarnowska, E., Maczewski, M. & Beresewicz, A. Effect of ischemic preconditioning on endothelial dysfunction and granulocyte adhesion in isolated guinea-pig hearts subjected to ischemia/reperfusion. J. Physiol. Pharmacol. 50, 617–628 (1999).
Zhao, J. L., Yang, Y. J., You, S. J., Cui, C. J. & Gao, R. L. Different effects of postconditioning on myocardial no-reflow in the normal and hypercholesterolemic mini-swines. Microvasc. Res. 73, 137–142 (2007).
Skyschally, A., Amanakis, G., Neuhauser, M., Kleinbongard, P. & Heusch, G. Impact of electrical defibrillation on infarct size and no-reflow in pigs subjected to myocardial ischemia–reperfusion without and with ischemic conditioning. Am. J. Physiol. Heart Circ. Physiol. 313, H871–H878 (2017).
Liu, G. S. et al. Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation 84, 350–356 (1991).
Ytrehus, K., Liu, Y. & Downey, J. M. Preconditioning protects ischemic rabbit heart by protein C activation. Am. J. Physiol. Heart Circ. Physiol. 266, H1145–H1152 (1994).
Schulz, R., Cohen, M., Behrends, M., Downey, J. M. & Heusch, G. Signal transduction of ischemic preconditioning. Cardiovasc. Res. 52, 181–198 (2001).
Heusch, G., Boengler, K. & Schulz, R. Cardioprotection: nitric oxide, protein kinases, and mitochondria. Circulation 118, 1915–1919 (2008).
Heusch, G. Molecular basis of cardioprotection: signal transduction in ischemic pre-, post-, and remote conditioning. Circ. Res. 116, 674–699 (2015).
Cohen, M. V. & Downey, J. M. Signalling pathways and mechanisms of protection in pre- and postconditioning: historical perspective and lessons for the future. Br. J. Pharmacol. 172, 1913–1932 (2015).
Schulz, R., Rose, J., Post, H. & Heusch, G. Involvement of endogenous adenosine in ischaemic preconditioning in swine. Pflügers Arch. 430, 273–282 (1995).
Goto, M. et al. Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ. Res. 77, 611–621 (1995).
Schulz, R., Post, H., Vahlhaus, C. & Heusch, G. Ischemic preconditioning in pigs: a graded phenomenon: its relation to adenosine and bradykinin. Circulation 98, 1022–1029 (1998).
Cohen, M. V., Yang, X.-M., Liu, G. S., Heusch, G. & Downey, J. M. Acetylcholine, bradykinin, opioids, and phenylephrine, but not adenosine, trigger preconditioning by generating free radicals and opening mitochondrial KATP channels. Circ. Res. 89, 273–278 (2001).
Schultz, J. E. L., Rose, E., Yao, Z. & Gross, G. J. Evidence for involvement of opioid receptors in ischemic preconditioning in rat hearts. Am. J. Physiol. 268, H2157–H2161 (1995).
Schulz, R., Gres, P. & Heusch, G. Role of endogenous opioids in ischemic preconditioning but not in short-term hibernation in pigs. Am. J. Physiol. Heart Circ. Physiol. 280, H2175–H2181 (2001).
Smith, R. M., Suleman, N., McCarthy, J. & Sack, M. N. Classic ischemic but not pharmacologic preconditioning is abrogated following genetic ablation of the TNFα gene. Cardiovasc. Res. 55, 553–560 (2002).
Dawn, B. et al. Tumor necrosis factor-α does not modulate ischemia/reperfusion injury in naive myocardium but is essential for the development of late preconditioning. J. Mol. Cell Cardiol. 37, 51–61 (2004).
Skyschally, A. et al. Bidirectional role of tumor necrosis factor-α in coronary microembolization: progressive contractile dysfunction versus delayed protection against infarction. Circ. Res. 100, 140–146 (2007).
Gysembergh, A. et al. Stretch-induced protection shares a common mechanism with ischemic preconditioning in rabbit heart. Am. J. Physiol. Heart Circ. Physiol. 274, H955–H964 (1998).
Cohen, M. V. & Downey, J. M. Adenosine: trigger and mediator of cardioprotection. Basic Res. Cardiol. 103, 203–215 (2008).
Schulz, R., Kelm, M. & Heusch, G. Nitric oxide in myocardial ischemia/reperfusion injury. Cardiovasc. Res. 61, 402–413 (2004).
Rossello, X. & Yellon, D. M. The RISK pathway and beyond. Basic Res. Cardiol. 113, 2 (2017).
Hadebe, N., Cour, M. & Lecour, S. The SAFE pathway for cardioprotection: is this a promising target? Basic Res. Cardiol. 113, 9 (2018).
Simkhovich, B. Z., Przyklenk, K. & Kloner, R. A. Role of protein kinase C in ischemic “conditioning”: from first evidence to current perspectives. J. Cardiovasc. Pharmacol. Ther. 18, 525–532 (2013).
Costa, A. D. T. et al. Protein kinase G transmits the cardioprotective signal from cytosol to mitochondria. Circ. Res. 97, 329–336 (2005).
Inserte, J. et al. cGMP/PKG pathway mediates myocardial postconditioning protection in rat hearts by delaying normalization of intracellular acidosis during reperfusion. J. Mol. Cell Cardiol. 50, 903–909 (2011).
Inserte, J. et al. Delayed phospholamban phosphorylation in post-conditioned heart favours Ca2+ normalization and contributes to protection. Cardiovasc. Res. 103, 542–553 (2014).
Juhaszova, M. et al. Role of glycogen synthase kinase-3beta in cardioprotection. Circ. Res. 104, 1240–1252 (2009).
Gomez, L., Paillard, M., Thibault, H., Derumeaux, G. & Ovize, M. Inhibition of GSK3beta by postconditioning is required to prevent opening of the mitochondrial permeability transition pore during reperfusion. Circulation 117, 2761–2768 (2008).
Nishino, Y. et al. Glycogen synthase kinase-3 inactivation is not required for ischemic preconditioning or postconditioning in the mouse. Circ. Res. 103, 307–314 (2008).
Nikolaou, P. E. et al. Investigating and re-evaluating the role of glycogen synthase kinase 3 beta kinase as a molecular target for cardioprotection by using novel pharmacological inhibitors. Cardiovasc. Res. 115, 1228–1243 (2019).
Boengler, K., Lochnit, G. & Schulz, R. Mitochondria “THE” target of myocardial conditioning. Am. J. Physiol. Heart Circ. Physiol. 315, H1215–H1231 (2018).
Heusch, G., Boengler, K. & Schulz, R. Inhibition of mitochondrial permeability transition pore opening: the holy grail of cardioprotection. Basic Res. Cardiol. 105, 151–154 (2010).
Hausenloy, D., Wynne, A., Duchen, M. & Yellon, D. Transient mitochondrial permeability transition pore opening mediates preconditioning-induced protection. Circulation 109, 1714–1717 (2004).
Liu, Y., Sato, T., O’Rourke, B. & Marban, E. Mitochondrial ATP-dependent potassium channels. Novel effectors of cardioprotection? Circulation 97, 2463–2469 (1998).
Boengler, K. et al. Connexin 43 in cardiomyocyte mitochondria and its increase by ischemic preconditioning. Cardiovasc. Res. 67, 234–244 (2005).
Boengler, K., Ungefug, E., Heusch, G., Leybaert, L. & Schulz, R. Connexin 43 impacts on mitochondrial potassium uptake. Front. Pharmacol. 4, 73 (2013).
Heinzel, F. R. et al. Impairment of diazoxide-induced formation of reactive oxygen species and loss of cardioprotection in connexin 43 deficient mice. Circ. Res. 97, 583–586 (2005).
Pain, T. et al. Opening of mitochondrial KATP channels triggers the preconditioned state by generating free radicals. Circ. Res. 87, 460–466 (2000).
Wegrzyn, J. et al. Function of mitochondrial Stat3 in cellular respiration. Science 323, 793–797 (2009).
Heusch, G., Musiolik, J., Gedik, N. & Skyschally, A. Mitochondrial STAT3 activation and cardioprotection by ischemic postconditioning in pigs with regional myocardial ischemia/reperfusion. Circ. Res. 109, 1302–1308 (2011).
Heusch, G. et al. STAT5 activation and cardioprotection by remote ischemic preconditioning in humans. Circ. Res. 110, 111–115 (2012).
Kohr, M. J. et al. Simultaneous measurement of protein oxidation and S-nitrosylation during preconditioning and ischemia/reperfusion injury with resin-assisted capture. Circ. Res. 108, 418–426 (2011).
Hernando, V. et al. Calpain translocation and activation as pharmacological targets during myocardial ischemia/reperfusion. J. Mol. Cell Cardiol. 49, 271–279 (2010).
Xuan, Y.-T., Guo, Y., Han, H., Zhu, Y. & Bolli, R. An essential role of the JAK–STAT pathway in ischemic preconditioning. Proc. Natl Acad. Sci. USA 98, 9050–9055 (2001).
Basalay, M. V., Davidson, S. M., Gourine, A. V. & Yellon, D. M. Neural mechanisms in remote ischaemic conditioning in the heart and brain: mechanistic and translational aspects. Basic Res. Cardiol. 113, 25 (2018).
Steensrud, T. et al. Pretreatment with the nitric oxide donor SNAP or nerve transection blocks humoral preconditioning by remote limb ischemia or intra-arterial adenosine. Am. J. Physiol. Heart Circ. Physiol. 299, H1598–H1603 (2010).
Merlocco, A. C. et al. Transcutaneous electrical nerve stimulation as a novel method of remote preconditioning: in vitro validation in an animal model and first human observations. Basic Res. Cardiol. 109, 406 (2014).
Skyschally, A. et al. Across-species transfer of protection by remote ischemic preconditioning with species-specific myocardial signal transduction by reperfusion injury salvage kinase and survival activating factor enhancement pathways. Circ. Res. 117, 279–288 (2015).
Gedik, N. et al. Potential humoral mediators of remote ischemic preconditioning in patients undergoing surgical coronary revascularization. Sci. Rep. 7, 12660 (2017).
Maciel, L., Oliveira, D. F., Verissimo da Costa, G. C., Bisch, P. M. & Nascimento, J. H. M. Cardioprotection by transfer of coronary effluent from ischemic preconditioned rat hearts: identification of cardioprotective humoral factors. Basic Res. Cardiol. 112, 52 (2016).
Lieder, H. R. et al. Vago-splenic axis in signal transduction of remote ischemic preconditioning in pigs and rats. Circ. Res. 123, 1152–1163 (2018).
Rohailla, S. et al. Acute, delayed and chronic remote ischemic conditioning is associated with downregulation of mTOR and enhanced autophagy signaling. PLoS ONE 9, e111291 (2014).
Kleinbongard, P. & Heusch, G. Extracellular signalling molecules in the ischaemic/reperfused heart — druggable and translatable for cardioprotection? Br. J. Pharmacol. 172, 2010–2025 (2015).
Gersh, B. J., Stone, G. W., White, H. D. & Holmes, D. R. Jr. Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: is the slope of the curve the shape of the future? JAMA 293, 979–986 (2005).
Homeister, J. W., Hoff, P. T., Fletcher, D. D. & Lucchesi, B. R. Combined adenosine and lidocaine administration limits myocardial reperfusion injury. Circulation 82, 595–608 (1990).
Vander Heide, R. S. & Reimer, K. A. Effect of adenosine therapy at reperfusion and myocardial infarct size in dogs. Cardiovasc. Res. 31, 711–718 (1996).
Baxter, G. F. et al. Adenosine A1 agonist at reperfusion trial (AART): results of a three-center, blinded, randomized, controlled experimental infarct study. Cardiovasc. Drugs Ther. 14, 607–614 (2000).
Bulluck, H., Sirker, A., Loke, Y. K., Garcia-Dorado, D. & Hausenloy, D. J. Clinical benefit of adenosine as an adjunct to reperfusion in ST-elevation myocardial infarction patients: an updated meta-analysis of randomized controlled trials. Int. J. Cardiol. 202, 228–237 (2016).
Duranski, M. R. et al. Cytoprotective effects of nitrite during in vivo ischemia–reperfusion of the heart and liver. J. Clin. Invest. 115, 1232–1240 (2005).
Lefer, D. et al. Sodium nitrite fails to limit myocardial infarct size: results from the CAESAR cardioprotection consortium [abstract LB645]. FASEB J. 28 (2014).
Siddiqi, N. et al. Intravenous sodium nitrite in acute ST-elevation myocardial infarction: a randomized controlled trial (NIAMI). Eur. Heart J. 35, 1255–1262 (2014).
Jones, D. A. et al. Randomized phase 2 trial of intracoronary nitrite during acute myocardial infarction. Circ. Res. 116, 437–447 (2015).
Mayr, M. et al. Loss of PKC-δ alters cardiac metabolism. Am. J. Physiol. Heart Circ. Physiol. 287, H937–H945 (2004).
Chen, L. et al. Opposing cardioprotective actions and parallel hypertrophic effects of δPKC and εPKC. Proc. Natl Acad. Sci. USA 98, 11114–11119 (2001).
Fryer, R. M. et al. PKC-δ inhibition does not block preconditioning-induced preservation in mitochondrial ATP synthesis and infarct size reduction in rats. Basic Res. Cardiol. 97, 47–54 (2002).
Lincoff, A. M. et al. Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI randomized controlled trial. Eur. Heart J. 35, 2516–2523 (2014).
Argaud, L. et al. Specific inhibition of the mitochondrial permeability transition prevents lethal reperfusion injury. J. Mol. Cell Cardiol. 38, 367–374 (2005).
Boengler, K., Hilfiker-Kleiner, D., Heusch, G. & Schulz, R. Inhibition of permeability transition pore opening by mitochondrial STAT3 and its role in myocardial ischemia/reperfusion. Basic Res. Cardiol. 105, 771–785 (2010).
Skyschally, A., Schulz, R. & Heusch, G. Cyclosporine A at reperfusion reduces infarct size in pigs. Cardiovasc. Drugs Ther. 24, 85–87 (2010).
Lie, R. H. et al. Post-conditioning with cyclosporine A fails to reduce the infarct size in an in vivo porcine model. Acta Anaesthesiol. Scand. 54, 804–813 (2010).
Karlsson, L. O., Bergh, N. & Grip, L. Cyclosporine A, 2.5mg/kg, does not reduce myocardial infarct size in a porcine model of ischemia and reperfusion. J. Cardiovasc. Pharmacol. Ther. 17, 159–163 (2012).
Piot, C. et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N. Engl. J. Med. 359, 473–481 (2008).
Ottani, F. et al. Cyclosporine A in reperfused myocardial infarction. The multicenter, controlled, open-label CYCLE trial. J. Am. Coll. Cardiol. 67, 365–374 (2016).
Botker, H. E., Cabrera-Fuentes, H. A., Ruiz-Meana, M., Heusch, G. & Ovize, M. Translational issues for mitoprotective agents as adjunct to reperfusion therapy in patients with ST-segment elevation myocardial infarction. J. Cell Mol. Med. 24, 2717–2729 (2020).
Ibanez, B. et al. Early metoprolol administration before coronary reperfusion results in increased myocardial salvage: analysis of ischemic myocardium at risk using cardiac magnetic resonance. Circulation 115, 2909–2916 (2007).
Ibanez, B. et al. Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the effect of metoprolol in cardioprotection during an acute myocardial infarction (METOCARD-CNIC) trial. Circulation 128, 1495–1503 (2013).
Garcia-Prieto, J. et al. Neutrophil stunning by metoprolol reduces infarct size. Nat. Commun. 8, 14780 (2017).
Roolvink, V. et al. Early administration of intravenous beta blockers in patients with ST-elevation myocardial infarction before primary PCI. J. Am. Coll. Cardiol. 67, 2705–2715 (2016).
Timmers, L. et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J. Am. Coll. Cardiol. 53, 501–510 (2009).
Alburquerque-Bejar, J. J. et al. Combination therapy with remote ischaemic conditioning and insulin or exenatide enhances infarct size limitation in pigs. Cardiovasc. Res. 107, 246–254 (2015).
Lonborg, J. et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur. Heart J. 33, 1491–1499 (2012).
Kyhl, K. et al. A post hoc analysis of long-term prognosis after exenatide treatment in patients with ST-segment elevation myocardial infarction. EuroIntervention 12, 449–455 (2016).
Dominguez-Rodriguez, A. et al. Effect of intravenous and intracoronary melatonin as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: results of the melatonin adjunct in the acute myocardial infarction treated with angioplasty trial. J. Pineal Res. 62, e12374 (2017).
Hausenloy, D. J. et al. Melatonin as a cardioprotective therapy following ST-segment elevation myocardial infarction: is it really promising? Reply. Cardiovasc. Res. 113, 1418–1419 (2017).
Galaup, A. et al. Protection against myocardial infarction and no-reflow through preservation of vascular integrity by angiopoietin-like 4. Circulation 125, 140–149 (2012).
Bouleti, C. et al. Angiopoietin-like 4 serum levels on admission for acute myocardial infarction are associated with no-reflow. Int. J. Cardiol. 187, 511–516 (2015).
Do Carmo, H., Arjun, S., Petrucci, O., Yellon, D. M. & Davidson, S. M. The caspase 1 inhibitor VX-765 protects the isolated rat heart via the RISK pathway. Cardiovasc. Drugs Ther. 32, 165–168 (2018).
Vicencio, J. M. et al. Plasma exosomes protect the myocardium from ischemia–reperfusion injury. J. Am. Coll. Cardiol. 65, 1525–1536 (2015).
Davidson, S. M. et al. Circulating blood cells and extracellular vesicles in acute cardioprotection. Cardiovasc. Res. 115, 1156–1166 (2019).
Duncker, D. J. et al. Effect of temperature on myocardial infarction in swine. Am. J. Physiol. 270, H1189–H1199 (1996).
Gotberg, M. et al. Optimal timing of hypothermia in relation to myocardial reperfusion. Basic Res. Cardiol. 106, 697–708 (2011).
Yang, X. et al. Cardioprotection by mild hypothermia during ischemia involves preservation of ERK activity. Basic Res. Cardiol. 106, 421–430 (2011).
Dai, W., Hale, S. & Kloner, R. A. Delayed therapeutic hypothermia protects against the myocardial no-reflow phenomenon independently of myocardial infarct size in a rat ischemia/reperfusion model. Int. J. Cardiol. 236, 400–404 (2017).
Dixon, S. R. et al. Induction of mild systemic hypothermia with endovascular cooling during primary percutaneous coronary intervention for acute myocardial infarction. J. Am. Coll. Cardiol. 40, 1928–1934 (2002).
Erlinge, D. et al. Rapid endovascular catheter core cooling combined with cold saline as an adjunct to percutaneous coronary intervention for the treatment of acute myocardial infarction (the CHILL-MI trial). J. Am. Coll. Cardiol. 63, 1857–1865 (2014).
Nichol, G. et al. Prospective, multicenter, randomized, controlled pilot trial of peritoneal hypothermia in patients with ST-segment-elevation myocardial infarction. Circ. Cardiovasc. Interv. 8, e001965 (2015).
Shinlapawittayatorn, K. et al. Low-amplitude, left vagus nerve stimulation significantly attenuates ventricular dysfunction and infarct size through prevention of mitochondrial dysfunction during acute ischemia–reperfusion injury. Heart Rhythm 10, 1700–1707 (2013).
Uitterdijk, A. et al. Vagal nerve stimulation started just prior to reperfusion limits infarct size and no-reflow. Basic Res. Cardiol. 110, 508 (2015).
Yu, L. et al. Low-level tragus stimulation for the treatment of ischemia and reperfusion injury in patients with ST-segment elevation myocardial infarction: a proof-of-concept study. JACC Cardiovasc. Interv. 10, 1511–1520 (2017).
Lindsey, M. L. et al. Guidelines for experimental models of myocardial ischemia and infarction. Am. J. Physiol. Heart Circ. Physiol. 314, H812–H838 (2018).
Lecour, S. et al. ESC working group cellular biology of the heart: position paper: improving the preclinical assessment of novel cardioprotective therapies. Cardiovasc. Res. 104, 399–411 (2014).
Hausenloy, D. J. et al. Novel targets and future strategies for acute cardioprotection: position paper of the European Society of Cardiology working group on cellular biology of the heart. Cardiovasc. Res. 113, 564–585 (2017).
Jones, S. P. et al. The NHLBI-sponsored consortium for preclinical assessment of cardioprotective therapies (CAESAR): a new paradigm for rigorous, accurate, and reproducible evaluation of putative infarct-sparing interventions in mice, rabbits, and pigs. Circ. Res. 116, 572–586 (2015).
Rossello, X. et al. CIBER-CLAP (CIBERCV Cardioprotection Large Animal Platform): a multicenter preclinical network for testing reproducibility in cardiovascular interventions. Sci. Rep. 9, 20290 (2019).
Heusch, G., Skyschally, A. & Schulz, R. The in-situ pig heart with regional ischemia/reperfusion — ready for translation. J. Mol. Cell Cardiol. 50, 951–963 (2011).
Heusch, G. Cardioprotection research must leave its comfort zone. Eur. Heart J. 39, 3393–3395 (2018).
Ferdinandy, P., Hausenloy, D. J., Heusch, G., Baxter, G. F. & Schulz, R. Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. Pharmacol. Rev. 66, 1142–1174 (2014).
Kleinbongard, P., Botker, H. E., Ovize, M., Hausenloy, D. J. & Heusch, G. Co-morbidities and co-medications as confounders of cardioprotection — does it matter in the clinical setting? Br. J. Pharmacol. https://doi.org/10.1111/bph.14839 (2019).
Cohen, M. V. & Downey, J. M. The impact of irreproducibility and competing protection from P2Y12 antagonists on the discovery of cardioprotective interventions. Basic Res. Cardiol. 112, 64 (2017).
Heusch, G. Reduction of infarct size by ischaemic post-conditioning in humans: fact or fiction? Eur. Heart J. 33, 13–15 (2012).
Heusch, G. & Gersh, B. J. Is cardioprotection salvageable? Circulation 141, 415–417 (2020).
Hausenloy, D. J. et al. Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomized controlled trial. Lancet 370, 575–579 (2007).
Thielmann, M. et al. Cardioprotective and prognostic effects of remote ischaemic preconditioning in patients undergoing coronary artery bypass surgery: a single-centre randomised, double-blind, controlled trial. Lancet 382, 597–604 (2013).
Hausenloy, D. J. et al. Remote ischemic preconditioning and outcomes of cardiac surgery. N. Engl. J. Med. 373, 1408–1417 (2015).
Meybohm, P. et al. A multicenter trial of remote ischemic preconditioning for heart surgery. N. Engl. J. Med. 373, 1397–1407 (2015).
Kottenberg, E. et al. Protection by remote ischaemic preconditioning during coronary artery bypass grafting with isoflurane but not with propofol anesthesia — a clinical trial. Acta Anaesthesiol. Scand. 56, 30–38 (2012).
Kottenberg, E. et al. Interference of propofol with signal transducer and activator of transcription 5 activation and cardioprotection by remote ischemic preconditioning during coronary artery bypass grafting. J. Thorac. Cardiovasc. Surg. 147, 376–382 (2014).
Andreadou, I. et al. Immune cells as targets for cardioprotection: new players and novel therapeutic opportunities. Cardiovasc. Res. 115, 1117–1130 (2019).
Hausenloy, D. J. et al. Cardiac innervation in acute myocardial ischaemia/reperfusion injury and cardioprotection. Cardiovasc. Res. 115, 1167–1177 (2019).
Rossello, X. & Ibanez, B. Infarct size reduction by targeting ischemic injury: back to square one. Circ. Res. 122, 1041–1043 (2018).
Davidson, S. M. et al. Multitarget strategies to reduce myocardial ischemia/reperfusion injury: JACC review topic of the week. J. Am. Coll. Cardiol. 73, 89–99 (2019).
Wei, M. et al. Repeated remote ischemic postconditioning protects against adverse left ventricular remodeling and improves survival in a rat model of myocardial infarction. Circ. Res. 108, 1220–1225 (2011).
Pryds, K. et al. Effect of long-term remote ischemic conditioning on inflammation and cardiac remodeling. Scand. Cardiovasc. J. 53, 183–191 (2019).
Pryds, K. et al. Effect of long-term remote ischemic conditioning in patients with chronic ischemic heart failure. Basic Res. Cardiol. 112, 67 (2017).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03155022 (2019).
Acknowledgements
The author receives support from the German Research Foundation (SFB 1116, B8) and the European Union COST ACTION (CA 16225).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Additional information
Peer review information
Nature Reviews Cardiology thanks S. Lavandero, A. Lochner, and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Glossary
- Mitochondrial permeability transition pore
-
(MPTP). High-conductance channel in the inner mitochondrial membrane that opens in response to increased concentrations of Ca2+ and inorganic phosphate. The molecular identity of the MPTP is not fully clear but seems to be formed from F1/F0 ATP synthase. MPTP opening is modulated by cyclophilin D.
- Necrosome
-
Complex of phosphorylated specific receptor-interacting serine/threonine-protein kinases with phosphorylated mixed-lineage kinase domain-like proteins; formation of this complex indicates the activation of necroptosis.
- No-reflow phenomenon
-
Lack of flow into the coronary microcirculation despite reopening of the previously occluded epicardial coronary artery; a consequence of vascular injury by ischaemia–reperfusion.
- Pre-infarction angina
-
Angina caused by reversible myocardial ischaemia in the hours and days before an acute myocardial infarction with irreversible injury.
- Killip class
-
Grading classification for the haemodynamic consequences of acute myocardial infarction, from I (no signs of heart failure) to IV (cardiogenic shock).
Rights and permissions
About this article
Cite this article
Heusch, G. Myocardial ischaemia–reperfusion injury and cardioprotection in perspective. Nat Rev Cardiol 17, 773–789 (2020). https://doi.org/10.1038/s41569-020-0403-y
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41569-020-0403-y